PAVM · PAVmed Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jan 2, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jan 2, 2026.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP adjusted (loss) income per share, basic and diluted non-GAAP | -$1.17 | Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PAVM
this stock
PAVmed Inc.
|
$41.38M | — | +20.0% | — | 0.3% |
|
ABT
Abbott Laboratories
|
$203.17B | -6.9% | +5.7% | 32.7 | 1.3% |
|
SYK
Stryker Corp
|
$126.37B | -6.3% | +11.2% | 34.1 | 2.2% |
|
MDT
Medtronic plc
|
$119.49B | -2.8% | +8.4% | 25.0 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.00B | -47.2% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jan 2, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PAVM | -0.5% | +9.2% | -48.6% | +4.6% | — |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +0.9% | +5.6% | -60.1% | +2.1% | — |